Transplant rejection is a complex immune response that occurs when a person’s body attacks a newly transplanted organ or tissue, treating it as a foreign invader rather than a helpful addition. With the right combination of preventive medications and careful monitoring, many cases of rejection can be managed successfully, allowing transplant recipients to live healthier lives with their new organs.

How Medical Teams Approach Transplant Rejection

When someone receives a transplanted organ, whether it’s a kidney, liver, heart, lung, or pancreas, their medical team focuses on several key goals: preventing the body from attacking the new organ, catching any signs of rejection early, and preserving the organ’s function for as long as possible. The approach to managing transplant rejection depends on many factors, including which organ was transplanted, how long ago the surgery took place, and the individual patient’s overall health condition.^[1]

Healthcare providers recognize that rejection is not necessarily a catastrophic event. In fact, some degree of rejection is quite common after organ transplantation, with about 15% to 20% of people who receive a new kidney experiencing some type of rejection episode. The severity varies considerably from person to person.^[2] What matters most is identifying rejection quickly and responding appropriately. Most rejection episodes can be reversed or controlled when caught early, before they cause irreversible damage to the transplanted organ.^[1]

Medical societies and transplant centers worldwide have developed comprehensive guidelines for preventing and treating organ rejection. These recommendations are based on decades of research and clinical experience. The standard approach involves matching donors and recipients as closely as possible before surgery, using medications to suppress the immune system afterward, and maintaining close contact between patients and their transplant teams throughout the recipient’s lifetime.^[4]

Meanwhile, researchers continue to explore new therapies through clinical trials. These studies investigate innovative approaches that might improve outcomes, reduce side effects from current medications, or help more patients keep their transplanted organs functioning for longer periods. The field of transplant medicine is constantly evolving as scientists learn more about how the immune system works and how to modulate its responses more precisely.^[7]

Standard Treatment Approaches for Preventing and Managing Rejection

The foundation of transplant rejection management begins even before the organ is placed in the recipient’s body. Healthcare providers perform extensive testing to match the donor and recipient as closely as possible. This process, called tissue typing, looks at specific proteins called antigens on the surface of cells. The more similar these antigens are between donor and recipient, the less likely the immune system will recognize the organ as foreign and attack it.^[1]

No two people except identical twins have perfectly matched tissue antigens. Because of this natural variation, doctors rely heavily on medications called immunosuppressants to prevent rejection. These drugs work by weakening the immune system just enough to stop it from attacking the transplanted organ, while still leaving the person with enough immunity to fight off serious infections. Without these medications, the body would almost always mount an immune response and destroy the foreign tissue.^[1]

The immunosuppressive treatment typically follows three phases. The first phase, called induction therapy, happens right around the time of surgery. Medicines are given through a vein before and immediately after the transplant to help prepare the body to accept the new organ. These powerful drugs give the transplant the best possible start.^[12]

The second phase, maintenance therapy, continues for as long as the person has the transplanted organ—essentially for the rest of their life. Patients usually take a combination of different medications every day. These drugs are typically started shortly after surgery and continued indefinitely. Common maintenance medications include azathioprine, which interferes with immune cell production, and corticosteroids, which reduce inflammation and dampen immune responses. Many patients also take newer agents that target specific parts of the immune system.^[4][13]

The third phase involves rejection treatment, which is used if the body starts to reject the organ despite preventive medications. If healthcare providers detect signs of rejection, they typically increase the dose of existing immunosuppressants or add new ones. Corticosteroids serve as the primary treatment for acute rejection episodes. For severe cases or when steroids don’t work well enough, doctors may use more powerful agents called T-cell-depleting antibodies, such as Thymoglobulin, which specifically target and remove the immune cells attacking the organ.^[7][1]

The duration of immunosuppressive therapy is lifelong for most transplant recipients. Regular blood tests are essential to monitor the levels of these medications in the bloodstream. If levels are too high, patients may experience worse side effects; if too low, the organ may not have adequate protection against rejection.^[12]

Like all medications, immunosuppressants can cause side effects. Common problems include an increased risk of infections, since the immune system is deliberately weakened. Patients may also develop diabetes, high blood pressure, or high cholesterol. Some people experience stomach problems or notice changes in their appearance. Over time, the weakened immune system also slightly increases the risk of certain cancers. Most of these side effects are manageable and tend to improve as the body adjusts to the medications. Regular monitoring helps healthcare providers catch and address problems early.^[12]

For certain types of rejection, particularly antibody-mediated rejection where the immune system produces antibodies against the transplanted organ, treatment becomes more complex. The most common approach is plasmapheresis, a procedure that filters antibodies out of the blood. However, the effectiveness of this treatment remains debated among medical experts. Other therapies used for antibody-mediated rejection include intravenous immunoglobulins, which are antibody preparations given through a vein, and anti-CD20 antibodies like rituximab, which target specific immune cells that produce antibodies.^[7]

Healthcare providers also use medications called complement inhibitors and proteasome inhibitors in some cases of antibody-mediated rejection, though research into their effectiveness continues. Management decisions depend heavily on when the rejection occurs and whether there are already chronic changes in the organ that might limit recovery.^[7]

Understanding the Different Types of Rejection

Transplant rejection isn’t a single, uniform process. Medical professionals recognize three distinct types of rejection, each occurring at different times after transplantation and requiring different approaches. Understanding these differences helps patients and their families know what to watch for and when rejection is most likely to occur.^[1]

Hyperacute rejection is the most dramatic and immediate form, occurring within minutes to hours after the transplant. This happens when the recipient already has pre-formed antibodies in their blood that immediately attack the donor organ. The reaction is so severe that the kidney or other organ is completely destroyed and must be removed right away to save the recipient’s life. Fortunately, hyperacute rejection is extremely rare today because doctors routinely perform blood typing and cross-matching tests before surgery to identify these incompatibilities. This type of rejection typically occurs only if a person receives an organ with an incompatible blood type, such as receiving a type A organ when they have type B blood.^[6][1]

Acute rejection can occur anytime from the first week after transplant to three months afterward, though it’s most common within the first six months. Some degree of acute rejection happens in many transplant recipients—it’s not unusual. About 15% or fewer of people who receive a deceased donor kidney transplant will experience an acute rejection episode. When caught early and treated promptly, acute rejection is often reversible. The likelihood of experiencing acute rejection decreases as time passes and the kidney continues functioning well. If someone doesn’t have an acute rejection episode within the first 12 months, they’re less likely to have one later, assuming they continue taking their medications as prescribed.^[2][6]

Chronic rejection develops slowly over months or years. This form results from the body’s constant, low-level immune response against the organ, which gradually causes scarring and damage to the transplanted tissue. Chronic rejection happens more often than acute rejection and can occur years after a successful transplant. The signs are usually subtle and easy to miss because the damage accumulates gradually rather than suddenly. Unfortunately, no medication currently exists to reverse chronic rejection once it’s established. However, controlling blood pressure, blood sugar levels, and cholesterol may help slow its progression. Once diagnosed, kidney function may continue for months or even years, though the organ will eventually lose function.^[1][6]

Within these categories, doctors further classify rejection by the mechanism involved. T-cell-mediated rejection (also called cellular rejection) occurs when specific white blood cells called T lymphocytes attack the transplanted organ. Antibody-mediated rejection happens when the immune system produces antibodies that bind to the blood vessels in the grafted organ, causing damage through a different pathway.^[2][7]

Recognizing the Warning Signs of Rejection

One of the most important things transplant recipients can do is learn to recognize potential signs of organ rejection. Early detection dramatically improves the chances of successful treatment and prevents permanent damage. However, many symptoms of rejection are nonspecific, meaning they could be caused by various problems, not just rejection. This is why it’s crucial to contact the transplant team immediately whenever concerning symptoms appear.^[2]

General symptoms that may indicate rejection include fever higher than 100 or 101 degrees Fahrenheit (38 degrees Celsius), flu-like symptoms such as chills, body aches, headaches, or nausea, and a general feeling of discomfort or illness. Some people experience pain or tenderness in the area where the organ was transplanted, though this is less common. Sudden weight gain of more than 2 to 4 pounds within 24 hours can signal fluid retention related to organ dysfunction.^[2][1]

The symptoms also vary depending on which organ was transplanted. For kidney transplant recipients, warning signs include producing less urine than usual or noticing swelling in the hands, feet, or ankles. People who received a heart transplant might develop shortness of breath or reduced ability to exercise. Liver transplant recipients should watch for yellowing of the skin or eyes and unusual bleeding or bruising. Those with pancreas transplants may notice their blood sugar levels becoming harder to control.^[1]

Many times, rejection produces no symptoms at all, especially in its early stages or in cases of chronic rejection. This is why regular follow-up appointments and blood tests are absolutely essential. Laboratory tests can detect changes in organ function before a person feels sick. For kidney transplants, doctors monitor a substance called creatinine in the blood. Rising creatinine levels often indicate the kidney isn’t working properly, which could signal rejection even when the patient feels fine.^[2]

How Doctors Diagnose Transplant Rejection

When rejection is suspected, doctors use several methods to confirm the diagnosis and determine its severity. Physical examination is always the first step. The healthcare provider will check the area around the transplanted organ, looking for tenderness, swelling, or other abnormalities. They’ll also assess vital signs like blood pressure, heart rate, and temperature.^[1]

Blood tests and other laboratory studies provide crucial information about organ function. For kidney transplants, tests measure creatinine, blood urea nitrogen (BUN), and other markers of kidney function. Heart transplant recipients undergo blood tests to check for heart muscle damage. Liver function tests evaluate how well a transplanted liver is working. These routine tests are performed at every follow-up visit, even when patients feel well, because they can detect problems before symptoms develop.^[1][2]

Various imaging studies help doctors visualize the transplanted organ and assess its structure and blood flow. Ultrasound is commonly used because it’s non-invasive, safe, and provides real-time images. For kidney transplants, a renal ultrasound can show the size of the kidney, look for fluid collections, and check blood flow through the organ’s vessels. Other imaging techniques include CT scans, chest x-rays for heart or lung transplants, and specialized studies like kidney arteriography or echocardiography for heart transplants.^[1][14]

However, the only definitive way to diagnose organ rejection is through a biopsy. During this procedure, a doctor removes a tiny piece of the transplanted organ using a needle. The tissue sample is then examined under a microscope by a pathologist, who can identify signs of immune system attack and classify the type and severity of rejection. Many transplant centers perform routine biopsies on a schedule, even when there are no symptoms, to catch rejection in its earliest stages. When rejection is suspected based on symptoms or lab tests, a biopsy confirms the diagnosis and guides treatment decisions.^[1][6]

For kidney biopsies, the procedure is typically done with local anesthesia, meaning the patient is awake but the area is numbed so they don’t feel pain. Biopsies of other organs follow similar principles, though the exact technique varies. While biopsies carry small risks like bleeding or infection, they provide invaluable information that cannot be obtained any other way.^[6]

Emerging Therapies Being Studied in Clinical Trials

While current immunosuppressive medications have dramatically improved transplant success rates, researchers recognize that these treatments are far from perfect. Many cause significant side effects, and they don’t prevent all rejection episodes. Some patients develop chronic rejection despite optimal medical management. This has driven intense research into new therapeutic approaches that might work better, cause fewer problems, or help specific groups of patients who don’t respond well to standard treatments.^[7]

Clinical trials are the pathway through which promising new treatments move from laboratory discoveries to actual patient care. These studies progress through distinct phases, each with specific goals. Phase I trials primarily test whether a new treatment is safe and determine appropriate dosing in a small number of people. Phase II trials expand to more patients and focus on whether the therapy actually works—does it prevent or treat rejection effectively? Phase III trials involve large numbers of patients and compare the new treatment directly against the current standard of care to see if the new approach offers meaningful advantages.^[4]

One area of active investigation involves developing more targeted immunosuppressive agents. Rather than broadly suppressing the entire immune system, these drugs aim to block very specific molecular pathways involved in organ rejection while leaving other immune functions intact. This approach could potentially reduce side effects like infections and cancer risk. Several complement inhibitors are being studied for antibody-mediated rejection. The complement system is part of the immune response that can damage transplanted organs, and blocking it represents a promising strategy.^[7]

Proteasome inhibitors, drugs originally developed for treating certain cancers, are being investigated for their ability to eliminate antibody-producing immune cells in cases of antibody-mediated rejection. Early studies suggest these medications might help some patients who don’t respond to conventional treatments, though more research is needed to establish their effectiveness and optimal use.^[7]

Researchers are exploring innovative approaches to prevent rejection without requiring lifelong immunosuppression. One concept involves inducing immune tolerance, where the recipient’s immune system learns to accept the transplanted organ as “self” rather than foreign. This would allow patients to eventually stop or greatly reduce their immunosuppressant medications. Various strategies are being tested, including special preparations of donor cells given around the time of transplant or manipulations of the recipient’s immune system before surgery. While true tolerance remains an elusive goal, progress continues in understanding how it might be achieved.^[4]

Advanced genetic and molecular techniques are helping scientists identify patients at higher risk for rejection before it occurs. Studies are investigating how changes in DNA methylation—chemical modifications that affect gene activity—in immune pathways might predict rejection risk. This could enable doctors to personalize immunosuppression, giving more intensive treatment to high-risk patients while potentially reducing medication burden for those at lower risk.^[4]

New biomarkers—measurable substances in blood or urine that indicate rejection—are being developed and tested. Better biomarkers could replace or supplement biopsies, making rejection monitoring less invasive and allowing even earlier detection. Some research focuses on measuring specific immune cells or their products, while other studies look at genetic material released by the transplanted organ when it’s under attack.^[4]

Clinical trials for transplant rejection treatments are conducted at major medical centers around the world, including locations in the United States, Europe, and other regions. Eligibility for these studies varies depending on the specific trial, but generally includes factors like the type of organ transplanted, time since transplant, history of rejection episodes, current medications, and overall health status. Some trials recruit patients actively experiencing rejection, while others enroll stable transplant recipients to test preventive strategies.^[4]

Preliminary results from various trials offer hope. Some studies of complement inhibitors have shown improvements in clinical parameters and positive safety profiles in patients with antibody-mediated rejection. Investigations of new immunosuppressive combinations report reduced rejection rates or better kidney function compared to older regimens. However, it’s important to emphasize that these are early findings. Many promising therapies from early trials don’t ultimately prove superior to existing treatments when tested in larger, more rigorous studies. This is why continued research through carefully designed clinical trials remains absolutely essential.^[7]

Most common treatment methods

• Immunosuppressive medications
  • Corticosteroids used as primary treatment for acute T-cell-mediated rejection and for general immune suppression
  • Azathioprine to interfere with immune cell production as part of maintenance therapy
  • T-cell-depleting agents like Thymoglobulin for severe or steroid-resistant acute rejection
  • Anti-CD20 antibodies such as rituximab that target specific immune cells producing antibodies
  • Induction therapy medicines given through a vein before and after transplant to prepare the body to accept the organ
  • Maintenance therapy medications taken as a combination for the entire life of the transplant
  • Lifelong daily medication regimens to suppress immune responses against the transplanted organ
• Plasmapheresis
  • Blood filtering procedure to remove antibodies in cases of antibody-mediated rejection
  • Most common treatment approach for antibody-mediated rejection though effectiveness remains debated
• Intravenous immunoglobulins
  • Antibody preparations given through a vein to help manage antibody-mediated rejection
  • Used in combination with other therapies for certain types of rejection
• Complement inhibitors
  • Medications that block the complement system, part of the immune response that damages organs
  • Used for antibody-mediated rejection with ongoing research into effectiveness
  • Being studied in clinical trials with preliminary positive results
• Proteasome inhibitors
  • Drugs that eliminate antibody-producing immune cells
  • Investigated for treatment of antibody-mediated rejection
  • Originally developed for cancer treatment, now being repurposed for rejection
• Tissue typing and matching
  • Pre-transplant testing to match donor and recipient antigens as closely as possible
  • HLA (human leukocyte antigen) matching to prevent rejection
  • Serum crossmatch testing to identify pre-formed antibodies
  • Blood type compatibility testing to prevent hyperacute rejection
• Organ biopsy
  • Definitive diagnostic procedure where tissue is removed with a needle and examined microscopically
  • Performed routinely on schedule or when rejection is suspected
  • Used to confirm diagnosis, identify type of rejection, and guide treatment decisions